Alport Syndrome clinical trials at UCSF
1 research study open to eligible people
Alport syndrome is a genetic condition that affects the kidneys. UCSF is conducting a clinical trial called "Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)" to test the safety and tolerability of a drug called bardoxolone methyl in people with chronic kidney disease (CKD). The study is for patients who meet specific qualifications.
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
open to eligible people ages 12 years and up
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.
San Francisco, California and other locations
Our lead scientists for Alport Syndrome research studies include Meyeon Park, MD.